fbpx
Colour
C C C C C
Text
T T
Skip To Content

FBC Funded Research

Every year, donors of Fighting Blindness Canada (FBC) fund research taking place in hospitals and universities across Canada, and around the world. This research is the backbone of our community and our primary tool for identifying the causes, treatments and, ultimately, cures for eye diseases.

FBC and its generous supporters are currently committed to funding 14 new and ongoing studies focused in three major areas of research:

Understand  – To comprehend the causes and effects of eye diseases
Preserve  – To retain and protect vision for people living with eye diseases
Restore  – To restore lost vision and cure blinding eye diseases

Scientific Title: Defining the Connections and Survival Mechanisms of Retinal Interneurons

Lead Investigator: Dr. David Picketts
Institution: Ottawa Hospital Research Institute
Granted: $240,000 over 3 years, July 2016 – June 2019

Dr. Picketts aims to UNDERSTAND vision loss by studying how inner retinal neurons mature, what factors are important for their survival and how they integrate and modulate photoreceptor signals. This fundamental knowledge will increase the success of emerging therapies to treat retinal degeneration.

Scientific Title: Whole Genome Sequencing of Patients with Early Onset Retinal Dystrophies

Lead Investigator: Dr. Elise Héon
Institution: The Hospital for Sick Children (SickKids)
Granted: $240,000 over 3 years, July 2016 – June 2019

At SickKids, Dr. Héon and her team are only able to identify mutations in approximately half of the people who are diagnosed with a retinal degenerative disease. In this project, Dr. Héon will use the latest sequencing technology and a targeted strategy to identify the greatest number of mutations possible and test why these mutations lead to vision loss. The team aims to UNDERSTAND why these mutations lead to retinal degeneration with the goal of developing new treatment strategies

Scientific Title: Temporal Identity Factors: Opening New Avenues for Cell Therapy in Retinal Degeneration

Lead Investigator: Dr. Michel Cayouette
Institution: Institut de recherches cliniques de Montréal
Granted: $125,000 from FBC / $990,000 from Canadian Institutes of Health Research (CIHR)
Duration: July 2016 – July 2021

Read more about this project

Scientific Title: Ocular Inflammatory Modulators in Age-related Macular Degeneration: A Role for Locally Accumulating Vitamin D

Lead Investigator: Dr. Jacob Rullo
Institution: Queen’s University
Granted: $60,000 over 2 years, October 2018 – October 2020

Dr. Jacob Rullo is studying the connection between vitamin D inside the eye and age-related macular degeneration (AMD), the leading cause of blindness in the aging population. Dr. Rullo will examine if vitamin D levels in the eye are lower in patients with AMD and study how AMD affects the levels of vitamin D. Considering the burden AMD has on the aging population, determining the role vitamin D plays could have enormous treatment potential.

Read more about this project

Scientific Title: Development of a Drug that Prevents Photoreceptor Death and Vision Loss
Lead Investigator: Dr. Philippe Monnier
Institution: Krembil Discovery Research Institute, University Health Network, Toronto
Granted: $240,000 over 3 years, July 2016 – June 2019

Dr. Philippe Monnier demonstrated that he could PRESERVE vision in three different laboratory models of retinitis pigmentosa (RP) by manipulating neogenin. Dr. Monnier is now focused on gathering essential pre-clinical data to enable a clinical trial testing a neogenin-based treatment for people living with blinding eye disease.

Read more stories about Dr. Monnier

Scientific Title: Why Does the Drug Valproic Acid (VPA) Prevent Some Forms of Blindness and Make Others Worse?
Lead Investigator: Dr. Orson Moritz
Institution: University of British Columbia
Granted: $240,000 over 3 years, July 2016 – June 2019

Dr. Moritz has shown that the drug valproic acid (VPA) prevents blindness in some genetic forms of RP but worsens it in other forms. In this study, he aims to PRESERVE vision by identifying the exact enzymes that are involved in these effects to learn how they are impacting vision loss with the goal of discovering additional drugs that could be used to prevent blindness.

Read more stories about Dr. Moritz

Scientific Title: Impact of Obesity on Age-Related Macular Degeneration
Lead Investigator: Dr. Przemyslaw (Mike) Sapieha
Institution: Hôpital Maisonneuve-Rosemont
Granted: $240,000 over 3 years, July 2016 – June 2019

Dr. Sapieha is exploring how the microbes of our body (the microbiome) affect obesity, the body’s immune response and ultimately the progression of AMD. By studying new wet-AMD pathways, he aims to identify new therapeutic targets for the disease that can help to PRESERVE sight.

Read more stories about Dr. Sapieha

Scientific Title: Investigating the Effect of a PEX6 Mutation on Peroxisome Structure and Function

Lead Investigator: Dr. Matthew Benson
Institution: University of Alberta
Granted: $60,000 over 2 years, October 2018 – October 2020

Dr. Benson is studying a genetic condition that leads to significant vision and hearing loss. Specifically, he is exploring how mutations in the PEX6 gene impact the structure and function of an important part of the cell called the “peroxisome.” Recent studies have shown that the drug chloroquine can improve peroxisome function, and Dr. Benson will test chloroquine as a potential sight-saving treatment for patients who have a PEX6 mutation.

Read more about this project

Scientific Title: Combined Cell and Gene Therapy Towards the Treatment of Age-Related Macular Degeneration

Lead Investigator: Dr. Andras Nagy
Institution: Lunenfeld Tanenbaum Research Institute, Mount Sinai Hospital
Granted: $770,000 over 4 years, July 2018 – June 2022

Dr. Nagy aims to RESTORE SIGHT by developing a new therapy that combines both stem cells and gene therapy to offer patients with wet age-related macular degeneration a ‘one shot’ permanent treatment.

Support provided by the Cedric Ritchie Fund to Cure Blindness

Read more stories about Dr. Nagy

Scientific Title: Bioengineered Cell Delivery Systems for the Transplantation of Stem Cell Progeny for Retinal Regeneration

Lead Investigator: Dr. Brian Ballios
Institution: University of Toronto
Granted: $80,000 over 3 years, March 2017 – March 2020

Dr. Ballios will use stem cells to generate the light-sensitive cells (photoreceptors) lost in many different blinding eye diseases and transplant those cells directly into the retina. He will explore more efficient ways of making photoreceptors from stem cells and develop new approaches to helping those transplanted cells survive and make connections in the damaged eye.

Read more

Scientific Title: Preclinical evaluation of an iPSC-derived photoreceptor therapeutic in canine models of retinitis pigmentosa

Lead Investigator: Dr. David Gamm
Institution: University of Wisonsin-Madison
Granted: $800,000 over 2 years, December 2018 – December 2020

Dr. Gamm is conducting critical pre-clinical studies to test the safety and effectiveness of a potential stem-cell replacement therapy for people living with late-stage retinitis pigmentosa.

Read more

Scientific Title: Anti-apoptotic therapy for the treatment of retinitis pigmentosa

Lead Investigator: Dr. Catherine Tsilfidis
Institution: Ottawa Hospital Research Institute
Granted: $430,000 over 2 years, December 2018 – December 2020

Dr. Tsilfidis is conducting essential pre-clinical studies to test the safety and effectiveness of a potential new gene therapy treatment for retinitis pigmentosa (RP). She is using a broad-based approach that targets a common feature to all forms of RP – the death of the photoreceptors. Her team is studying the X-linked inhibitor of apoptosis (XIAP) as a therapeutic for the treatment of RP. XIAP is a universal therapy that promotes photoreceptor survival, irrespective of the initial cause of disease.

Read more 

Scientific Title: Development of a Neogenin Based-Strategy to Prevent Photoreceptor Degeneration

Lead Investigator: Dr. Philippe Monnier
Institution: Krembil Research Institute
Granted: $200,000 over 2 years, December 2018 – December 2020

Dr. Monnier is developing a new drug that has the potential to preserve both rod and cone photoreceptors. His research plan includes key components of a full drug development pipeline that extends from discovery of lead compounds to a translational strategy aimed at initiating clinical trials. Dr. Monnier has evidence that this drug could be effective for people living with retinitis pigmentosa as well as other diseases that involve the loss of photoreceptor cells, such as age-related macular degeneration.

Read more 

Scientific Title: Developing a “photo-switch” drug for light-sensitive cells

Lead Investigator: Dr. Richard Kramer
Institution: University of California, Berkeley
Granted: $300,000 over 3 years, May 2018 – May 2021

Dr. Kramer is developing a “photo-switch” drug with the potential to restore sight by “switching” cells that are not light-sensitive into cells that are light-sensitive. We are proud to be funding Dr. Kramer’s research in partnership with the Foundation Fighting Blindness in the United States. We collaborate closely with our friends south of the border to ensure that we are not duplicating efforts. We strategically work together to better achieve our shared goal of driving the development of new sight-saving treatments.

Read more 

Latest FBC-Funded Research News View All

Sep 5, 2019

Last year Fighting Blindness Canada launched its Vision Care Pathways (VCP) online tool, a set of resources and guides for people living with eye diseases. These diseases include rare genetic disorders such…

Read More
Dr. Mike Sapieha holding microphone
Jul 9, 2019

FBC-funded scientist Dr. Mike Sapieha is an associate professor at the University of Montreal. This year, he was the recipient of ARVO’s prestigious Cogan Award, which recognizes an outstanding researcher under the…

Read More
Stem Cells
Jun 5, 2019

Dr. David Gamm is a pediatric ophthalmologist investigating how stem cells can be used as a potential treatment for retinitis pigmentosa (RP) and age-related macular degeneration (AMD). Dr. Gamm’s research is supported…

Read More

Join the Fight!

Learn how your support is helping to bring a future without blindness into focus! Be the first to learn about the latest breakthroughs in vision research and events in your community by subscribing to our eNews.

I have read and accepted the privacy policy